Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemiaKARP, Judith E; VENER, Tatiana I; CARRAWAY, Hetty E et al.Blood. 2012, Vol 119, Num 1, pp 55-63, issn 0006-4971, 9 p.Article

Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemiaKAUFMANN, Scott H; KARP, Judith E; MAURER, Matthew J et al.Haematologica (Roma). 2011, Vol 96, Num 11, pp 1619-1626, issn 0390-6078, 8 p.Article

Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemiaKARP, Judith E; GARRETT-MAYER, Elizabeth; LEVIS, Mark J et al.Haematologica (Roma). 2012, Vol 97, Num 11, pp 1736-1742, issn 0390-6078, 7 p.Article

High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host diseaseLUZNIK, Leo; BOLANOS-MEADE, Javier; KASAMON, Yvette et al.Blood. 2010, Vol 115, Num 16, pp 3224-3230, issn 0006-4971, 7 p.Article

A clinically relevant population of leukemic CD34⁺CD38^- cells in acute myeloid leukemiaGERBER, Jonathan M; DOUGLAS SMITH, B; GRIFFIN, Constance A et al.Blood. 2012, Vol 119, Num 15, pp 3571-3577, issn 0006-4971, 7 p.Article

Phase I and Pharmacologic Trial of Cytosine Arabinoside with the Selective Checkpoint 1 Inhibitor Sch 900776 in Refractory Acute LeukemiasKARP, Judith E; THOMAS, Brian M; MACKEY, Karen et al.Clinical cancer research (Print). 2012, Vol 18, Num 24, pp 6723-6731, issn 1078-0432, 9 p.Article